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Background. The diagnosis of fibrotic scar tissue in arrhythmogenic right ventricular 
cardiomyopathy (ARVC) and other cardiomyopathies is crucial as it forms the substrate for 
ventricular tachycardia (VT) and fibrillation (VT). Signal-averaged electrocardiography 
(SAECG) abnormalities are frequent in ARVC and in other cardiomyopathy-related ventricular 
arrhythmias. The correlation between cardiovascular magnetic resonance (CMR) late 
gadolinium enhancement (LGE) and parameters of SAECG in ARVC is not known.  
 
Method. Thirty-five patients [median age 32 years (IQR 25 – 46)] referred to the ARVC 
Registry at Groote Schuur Hospital were included in this retrospective study. SAECG was 
performed with high-amplification and filtered using bidirectional Butterworth filters between 
40 and 250 Hz. A filtered averaged QRS (fQRS) was obtained and analysed for fQRS duration, 
low amplitude signal duration <40 mV (LAS40), and root-mean-square voltage in the last 40ms 
of the QRS (RMS40). LGE acquired at 5 to 20 minutes after intravenous administration of 
gadolinium (0.1mmol/kg to 0.2mmol/kg of body mass) was assessed. We evaluated the 
correlation between SAECG parameters and the presence of LGE. 
Results. Sixteen patients had definite ARVC, 5 had possible ARVC, 4 had idiopathic VT/VF, 
2 had Athlete’s heart, 1 had dilated cardiomyopathy (DCM), 1 had hypertrophic 
cardiomyopathy (HCM), 1 had SVT and 1 had pericardial constriction.  LGE was present in 13 
(81%) ARVC patients, 2 (40%) with possible ARVC, 1 (50%) with athlete’s heart and in all 
patients with DCM and HCM. Patients with idiopathic VT/VF, pericardial constriction and 
supraventricular tachycardias had no myocardial LGE on CMR. Comparing patients with LGE 
and those without LGE on CMR, there were no differences in fQRS, (114ms [102.3 – 119] 
versus 111ms [99.5 -130], p = 0.608); LAS40 (34.5ms [16.8 - 40.8] versus 31ms [27.5 – 45], 
p = 0.566) and a RMS40 (23.5 µV [14.3 – 47.5] versus 33 µV [18.5 – 43.5], p= 0.621), 
respectively. LGE was present in 6 (60%) patients who had VT at presentation, in 9 (56%) 
with VT at baseline or follow-up and in all (2) patients who survived cardiac arrest. Three one-
way analyses of variance (fQRS vs LGE, LAS40 vs LGE and RMS40 vs. LGE) confirmed that 
there was no correlation between LGE technique on CMR and SAECG for the detection of 
myocardial fibrosis in ARVC and other myocardial disorders: for fQRS F(1 , 33) = 1.47, p = 
0.23, 2 = 0.02; for LAS40 F(1 , 33) =0.95, p = 0.34, 2 = 0.02 and for RMS40 F(1 , 33) = 0.36, 
p= 0.85, 2 = 0.02. 
Conclusion. In this study comparing assessment of myocardial fibrosis by LGE CMR and 
SAECG, there was no correlation between CMR and SAECG in detection of myocardial 
fibrosis in ARVC and other cardiovascular diseases.  
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Introduction, Literature Review and Study Rationale 
INTRODUCTION 
EPIDEMIOLOGY OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY  
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disorder 
characterised by fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow 
tract and/or apex of the right ventricle. The prevalence of ARVC in the general adult population 
is estimated to be approximately 1 in 2000 to 1 in 5000.1 The disease affects men more 
frequently than women with an approximate ratio of 3:1. ARVC is a well-identified cause of 
sudden cardiac death (SCD) in young adults, accounting for approximately 11% overall of 
SCD cases.2  
 
CLINICAL MANIFESTATIONS OF ARRHYTHMOGENIC RIGHT VENTRICULAR 
CARDIOMYOPATHY  
The clinical presentation of ARVC is variable, ranging from lack of symptoms to palpitations, 
syncope, chest pain, dyspnoea and, rarely, to SCD. Palpitations and syncope may be the 
manifestations of ventricular arrhythmias. Ventricular arrhythmias range from frequent 
premature ventricular contractions (PVCs) to sustained ventricular tachycardia (VT); the 
frequency of which is dependent on the severity of the disease.3 A non-sustained or sustained 
VT is the most common ventricular arrhythmia in ARVC and originates in the right ventricle 
(RV), and in particular, the RV outflow tract (RVOT), and therefore has left bundle branch 
block (LBBB) morphology.3,4 Furthermore, PVCs can also arise from the RVOT in ARVC; in 
such cases it becomes paramount to differentiate ARVC from idiopathic RVOT tachycardia as 
the management and prognosis is different.5  
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In trying to address the dilemma of the clinical diagnosis of ARVC, an expert consensus group 
proposed diagnostic criteria in 1994 (Table 1).6 These criteria were very specific to ARVC but 
lacked sensitivity in diagnosing milder or atypical presentations. They were later revised in 
20106 and now incorporate advances made in both imaging and diagnostic technology and 
genetics. The revised criteria now include parameters from two-dimensional (2D) 
echocardiography, cardiovascular magnetic resonance (CMR) imaging, RV angiography, 
signal-averaged electrocardiogram (SAECG), 12 lead electrocardiogram (ECG) and 
endomyocardial biopsy (EMB).  
 
In resource-limited settings, the diagnosis of ARVC is often a balancing act between available 
resources, patient clinical profile and the sensitivity and specificity of available diagnostic tools. 
In such settings it becomes imperative to explore data comparing different diagnostic 
modalities against each other.  
 
CARDIOVASCULAR MAGNETIC RESONANCE IN ARRHYTHMOGENIC RIGHT 
VENTRICULAR CARDIOMYOPATHY AND OTHER CARDIOMYOPATHIES 
To appreciate the use of CMR in the diagnosis of ARVC it is imperative to first conceptualise 
how magnetic resonance (MR) functions and how this is applied in the context of ARVC 
diagnosis. Further, it is important to be cognisant of other cardiac pathologies that may mimic 
ARVC on the CMR; these warrant discussion as they may cause diagnostic dilemmas and are 
discussed later. CMR use in the diagnosis of cardiovascular diseases (CVD) can broadly be 
divided into structural (anatomical) and functional (physiology) assessment of the heart. The 
usefulness of CMR in specific diseases as advised by Consensus Report Panel on the Clinical 







Table 1: Clinical Indications for CMR 
Class Indication 
I provides clinically relevant information and is usually appropriate; may be used as 
first line imaging technique; usually supported by substantial literature 
II provides clinically relevant information and is frequently useful; other techniques 
may provide similar information; supported by limited literature 
III provides clinically relevant information but is infrequently used because information 
from other imaging techniques is usually adequate 




In particular reference to ARVC, CMR is helpful in determining whether 1) RV function is 
normal or abnormal; 2) to accurately calculate RV volumes and ejection fraction (EF); 3) to 
assess the presence of RV regional wall motion abnormalities, wall thinning or aneurysmal 
formation; 4) to assess the presence of RV fatty infiltration; 5) assess the presence of RV 
myocardial fibrosis using late gadolinium enhancement (LGE); 6) assess whether there is LV 
involvement.  
 
With regards to cardiomyopathies in general, late gadolinium enhancement (LGE) refers to 
regions of scar, necrosis, and/or inflammation discriminated from normal tissue by prolonged 
retention of gadolinium-based contrast agents.8 Recently, there has been growing interest in 
exploiting the role of myocardial fibrosis, an integral pathophysiologic component of dilated 
cardiomyopathy (DCM), as a biomarker for guiding patient management and determining 
prognosis.9 Fibrosis can occur in 2 forms that can be detected by CMR:10 (A) irreversible 
replacement fibrosis which corresponds to the presence of LGE and (B) diffuse interstitial 
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fibrosis which better corresponds to findings on T1-mapping. Furthermore, in 
cardiomyopathies due to ischaemic heart disease (IHD) Abdel-Aty et al found LGE accurately 
delineates infarction as defined by histology at various time points following injury.11 In genetic 
cardiomyopathies like hypertrophic cardiomyopathy (HCM), CMR is more sensitive for the 
identification of more unusual sites of hypertrophy and for apical HCM than 
echocardiography.12 In their study assessing the accuracy of LGE for predicting microscopic 
myocardial scarring in biopsied specimens of hypertrophic cardiomyopathy, Konno et al 
reported the LGE in the ventricular septum had an excellent sensitivity (100%) with a low 
specificity (40%) whilst the whole heart had 100% sensitivity and 27% specificity.13  Between 
half and two-thirds of patients with HCM may have LGE with a characteristic pattern of patchy 
involvement, particularly at the LV/RV insertion sites and in those walls with the greatest 
hypertrophy.9 In certain cases of ARVC, the RV free wall can be the site of LGE14; the difficulty 
of this definitive observation being (1) a thin RV wall, (2) discriminating from RV fat and (3) the 
technique requires significantly different inversion times compare with the LV.15 
 
SIGNAL-AVERAGED ELECTROCARDIOGRAM IN ARRHYTHMOGENIC RIGHT 
VENTRICULAR CARDIOMYOPATHY 
SAECG is a computerised technique for detecting subtle abnormalities in the surface ECG 
that are not visible to the naked eye. The SAECG is derived by computing the arithmetic mean 
of multiple ECG complexes. This process increases the signal-to-noise ratio (SNR) of cardiac 
potentials and enables the detection of much smaller (i.e. microvolt-level) signals than would 
otherwise be undiscernible from the surface ECG.16 By detecting low-amplitude signals at the 
end of the QRS complex, referred to as ventricular late potentials, the SAECG allows for the 
diagnosis of delayed ventricular depolarisation which can be the result of myocardial scar 
tissue (fibrosis).17 The use of SAECG in the detection of fibrosis in ARVC has therefore been 
studied extensively and the presence of ventricular late potentials is a minor task force criterion 
in the diagnosis of ARVC. The sensitivity and specificity of an abnormal SAECG in ARVC has 
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been reported as 57% and 95% respectively.18 In 1991, a statement by a Task Force 
Committee of the European Society of Cardiology, the American Heart Association and the 
American College of Cardiology on the Standards for Analysis of Ventricular Late Potentials 
Using High-Resolution or Signal-Averaged Electrocardiography proposed the use of following 
criteria in determining the presence of late ventricular potentials19 (Table 2).  
 
Table 2: Criteria for the presence of late ventricular potentials 
• filtered QRS (fQRS) duration  114ms 
• low-amplitude (<40 μV) signal duration (LAS40)  38ms 
• root mean square voltage (RMS40) in the terminal 40ms of the fQRS  20μV 
 
 
ARVC is a progressive disease and the difficulty in making the diagnosis at various stages 
further reiterate this notion. It is therefore no surprise there is no single gold-standard 
investigation. 
 
Rationale for this research 
The incidence and clinical significance of LGE in cardiomyopathy patients, especially ARVC, 
with late potentials on SAECG has not been systemically evaluated. This study investigates 
the clinical utility of the LGE technique of CMR in relation to SAECG in the detection of 
myocardial fibrosis in ARVC patients and other cardiomyopathies. Such a comparison has 
never been performed before. Additional novelty of the study lies in the premise that a positive 
correlation of the 2 modalities would likely necessitate a modification or, at the least, a revision 
of the current Task Force Criteria17 with the inclusion of the LGE on CMR as one of the 
diagnostic criteria thus further increasing the diagnostic sensitivity of CMR. The value 
proposition of assessing utility and accuracy of SAECG for assessment of myocardial fibrosis 
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is because CMR is expensive, not widely available, and the expertise for its performance and 
analysis lacking in many parts of sub-Saharan Africa.  
 
Hypothesis 
There is no correlation of the LGE technique in CMR and SAECG in the detection of 
myocardial fibrosis in ARVC. 
 
STUDY AIMS AND OBJECTIVES 




Correlation of signal-averaged ECG and LGE CMR in assessment of myocardial fibrosis in 
patients referred with suspected ARVC 
 
SECONDARY OBJECTIVES 
Assess other cardiac parameters (including cardiac chamber size, function, wall thickness, 
strain and viability) using CMR, in patients referred with suspected ARVC.  
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METHODS 
This was a retrospective sub-study based on selected patients incorporated into IMHOTEP 
(The African Cardiomyopathy and Myocarditis Registry Programme). IMHOTEP is a multi-
centre, multi-national hospital-based prospective study of the clinical characteristics, causes, 
treatment and outcome of cardiomyopathies and myocarditis in children and adults from 
referral centres in Africa. Prevalent cases of the cohort study included are from the Groote 
Schuur Cardiomyopathy Clinic and South African ARVC Registry; whilst the incident cases 
are all newly diagnosed cardiomyopathy or myocarditis cases from Groote Schuur Hospital.  
 
Study population 
We conducted a retrospective study of patients referred to Groote Schuur Hospital Cardiac 
Clinic from 01 February 1996 – 31 May 2018 with suspected ARVC that had been evaluated 
for incorporation into IMHOTEP. Patients were included if they had undergone a complete 
cardiac examination including history, physical examination, 12 lead ECG, SAECG and 
gadolinium contrast-enhanced CMR. Patients were excluded from the study if they had (1) 
atrial fibrillation at the time of SAECG as variations in QRS complexes in atrial fibrillation affect 
validity of SAECG (2) a pacemaker at the time of SAECG as late potentials during a normal 
unpaced rhythm were being assessed and  (3)  an unfiltered QRS ≥ 110ms. 
Data collection and measurements 
Patient demographics, including age, sex, weight, height were obtained from the patients’ 
clinic folders by IMHOTEP investigators at the time of referral and stored on the secure 
database (username and password protected), governed by the University of Cape Town. 
Anonymised data was provided to the sub-study investigators. Data collected included 
patients’ history and symptoms were also be obtained and documented as dyspnoea (New 
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York Heart Association classification, NYHA 1-4), paroxysmal nocturnal dyspnoea, orthopnea, 
oedema, chest pain, palpitations and syncope. History of hypertension, type 2 diabetes 
mellitus, ischemic heart disease, hypercholesterolemia and rheumatic fever was recorded. 
Results of patients’ investigations was obtained from the clinic folders and archives of the 
South African ARVC registry. These included ECGs, SAECGs, chest radiographs, 
echocardiograms and CMR.  Laboratory results such as creatinine, haemoglobin were 
obtained from NHLS records, using the Labtrak and DISA systems. The data was 
independently reviewed by the ARVC diagnostic panel and was entered in to an Microsoft 
Excel Spreadsheet.  
SAECG 
The SAECG had been conducted using a General Electric (GE) MAC5500 (General Electric, 
Boston, Massachusetts, USA). The quantitative SAECG variables of the filtered QRS that 
were measured are: (1) total duration of fQRS, (2) duration of the low-amplitude signals 
(<40mV) in the terminal portion (LAS40) and (3) root-mean square voltage of the last 40ms 
(RMS40). Ventricular late potentials were considered positive when > 1 of the following criteria 
were fulfilled: (1) fQRS  114ms, (2) LAS40  38ms and RMS40  20µV, in the absence of a 
QRS duration of ≥110 ms on the standard ECG. 
CMR 
CMR had been performed using a 1.5T Siemens Symphony (VB 13, Siemens Healthcare, 
Erlangen, Germany) according to a standardised protocol. The following cardiac parameters 
were documented: (a) LV and RV volumes, mass and function, (b) Myocardial tissue 
characterisation using dual inversion recovery T2-weighted imaging and T1-weighted 
imaging, (c) Velocity-encoded 2-D phase contrast (flow) imaging, and (d) LGE imaging for 
viability and fibrosis assessment. LGE images acquired at 5 to 20 minutes after an intravenous 
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administration of gadolinium (0.1mmol/kg to 0.2mmol/kg of body mass) was reported when it 
was detected in more >1 imaging plane, using cross-plane localizers to confirm the position.  
 
Statistical analysis 
Data was analysed using statistical software (Version: 26.0.0.0 IBM Statistical Package for 
Social Sciences – SPSS, Armoyonk, NY, USA). Descriptive statistics were used to describe 
the study population.  Categorical data has been reported as number and proportion. Chi-
squared test of equal proportions was used to determine the difference between categorical 
data.  Continuous variables were tested for normality using Shapiro-Wilks and a histogram for 
visualisation.  Normally distributed data was reported as mean and standard deviation, and 
Independent t-test (2 samples) and Anova (more than 2 samples) were used to determine 
differences. Non-normally distributed data has been reported as median and interquartile 
range (IQR), and Wilcoxon sum rank (2 samples) and Kruskal-Wallis (more than 2 samples) 
were used to determine differences. Cox proportional hazard regression analysis was used to 
explore risk of adverse outcomes.  Kaplan-Meier survival analysis was done to determine 
transplant-free survival. A composite primary outcome measure of death or cardiac 
transplantation was used. All statistical tests are two sided, at α = 0.05. 
 
Ethical considerations 
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL 
Ethics approval was granted by the Faculty of Health Sciences Human Research Ethics 
Committee (HREC) with the REFERENCE: 787/2019. 
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INFORMED CONSENT 
As the study was retrospective, no specific consent was obtained for this study, however, 
informed consent for inclusion into IMHOTEP (HREC 766/2014) or the ARVC Registry of 
South Africa (HREC 047/2003) had been previously obtained from all participants. 
 
OTHER ETHICAL CONSIDERATIONS 
All patient data was anonymised and an alpha numeric nomenclature identification number 
was used for each participant in respect of confidentiality. No personal/identifying details were 
utilised in the analysis. Data and analysis records were kept in a secure computer and via an 




CMR is a safe and non-invasive technique with no known risk when appropriately supervised. 
It does not involve ionising radiation. Participants with ferromagnetic objects in their bodies or 
with implanted devices which can be damaged by the CMR magnet would have been excluded 
from clinical studies. All participants entering the scanner room had been screened for such 
objects. Gadolinium contrast is widely used for clinical indications in CMR and is safe. 
Occasionally it may cause a mild headache, nausea, itching and very rarely (< 1 in 1000) a 
more severe allergic reaction. It is cleared within hours by the body. Gadolinium has been 
associated with nephrogenic systemic fibrosis in patients with severe renal dysfunction; 
hence, all patients with glomerular filtration rate (GFR) < 30 ml/min (stage 3-5 renal disease) 




Enrolment and diagnosis 
In this sub-study, we looked at a total of 162 patients with suspected ARVC who were referred 
to the ARVC Registry for evaluation at Groote Schuur Hospital Cardiac Clinic from 01 February 
1996 – 31 May 2018. Of the 162 patients referred, 40 patients had had both SAECG and LGE 
CMR performed (Figure 1).  Of the 40 patients, only 35 had a valid SAECG (unfiltered QRS 
<110ms) and thus were eligible for the study. 
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 Figure 1: Study population 
162 with suspected ARVC  
CMR with LGE  





Study population = 35 
 23 
Demographics and baseline clinical characteristics 
Table 4 outlines the baseline characteristics for 35 patients included in the study, comparing 
those with (n = 17) and without (n = 18) LGE on CMR.  The most prevalent condition was 
ARVC (45.7%) fulfilling either definite (34.4%) or borderline (11.4%) criteria.  Possible early 
ARVC was considered in 14.3% of cases, however due to insufficient TFC a diagnosis of 
ARVC could not be confirmed. Alternative cardiac diagnoses were made in the remaining 
cases; idiopathic RVOT VT/VF (11.4%), athlete’s heart (5.7%), DCM (2.9%), HCM (2.9%), 
supraventricular tachycardia – SVT (2.9%) and pericardial constriction (2.9%). There was 
notable diagnostic variation between the groups; those with evidence of myocardial disease 
were more likely to have LGE, whereas LGE was not observed in patients with primary 
arrhythmias (Idiopathic VT/VF or SVT).   
 
The median age of presentation was 32 years (IQR 25- 46) with a male predominance 
(65.7%). Patients of mixed ancestry and Caucasians constituted 45.7% and 34.3% 
respectively, with 14.3% and 5.7% of the cohort represented by Black African and patients of 
South-East Asian descent.  There were no statically significant differences in demographic 
profiles between the LGE negative and LGE positive groups.  
 
All patients were symptomatic at presentation. The most prevalent presenting compliant was 
palpitations (77%), followed by pre-syncope (42.9%), chest pain (40%), syncope (37.1%) and 
dyspnoea (9%). Twenty-eight percent had VT at presentation whilst a small number presented 
having survived cardiac arrest (5.7%). Four patients underwent cardiac radiofrequency 










Table 4. Baseline and demographic parameters 
 
Participant characteristics All 
n = 35 
LGE –  
n = 17 
LGE+ 




Possible ARVC (%) 
DCM (%) 
HCM (%) 
Athlete’s heart (%) 
Idiopathic VT/VF (%) 
Pericardial constriction (%) 































Age of onset in years* 
     Mean (±SD) 
     Median (IQR) 
 
34.3 ±13.3 
32.0 (25 – 46) 
 
32.2 ±11.7 
30 (22.5 – 42.0) 
 
36.2 ±14.7 




Male sex, n (%) 23 (65.7) 9 (52.9) 14 (77.8) 0.122 
Ethnicity  
     Caucasian (%) 
     Black African (%) 
     Mixed ancestry (%) 

















































VT at presentation (%) 
VT at baseline or follow-up (%) 

















Previous ablation (%) 4 (11.4) 1 (5.8) 3 (16.7)  
ICD implantation (%) 15 (42.9) 7 (41.2) 8 (44.4) 0.845 
*Shapiro Wilks, p 0.289 
 
Baseline investigations 
There was no significant difference in the presence of a sinus rhythm between those with and 
without LGE on CMR. The unfiltered QRS tended to be longer in patients with LGE on CMR 
compared to those without LGE (95.9 ±9.9 vs 88.1 ±10.3; p = 0.967), but did not reach 
statistical significance. Late potentials also tended to be more prevalent in patients with LGE 
on CMR compared to those without (61.1% vs 35.3% p = 0.127), but without statistical 
significance (Table 5).  
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Further analysis of the late potential parameters, though not significant, revealed RMS40 and 
fQRS had greater differences between the LGE positive and LGE negative groups (15% and 
14.7%, respectively) than HFLA < 40µV ( 9.4%, p =0.555). The median fQRS duration in those 
with LGE was prolonged, 114ms (IQR 102.3 – 119) compared to 111ms (IQR 99.5 -130) in 
those without with a p = 0.608 highlighting no statistically significant difference. Even though 
the median RMS40 was lower 23.5 µV (IQR 14.3 – 47.5) in the group with LGE when 
compared to 33 µV (IQR 18.5 – 43.5) in the group without, the  p value is 0.358 and therefore 
this observed difference was not significant. (Table 5). 
Table 5. Standard ECG and SAECG 
 All 
n = 35 
LGE – 
n = 17 
LGE+ 
n = 18 
p-value 
ECG data 
Sinus rhythm (%) 
Heart rate (%) 


















Positive for late potentials (%) 
Filtered QRS ≥ 114ms (%) 
Terminal QRS ≥ 38ms (%) 
RMS ≤ 20µV (%) 
Filtered QRS duration (ms)* 
Mean ±SD 
Duration of terminal QRS < 40µV (ms) 
Mean ±SD 
























































Three one-way analyses of variance (fQRS vs LGE, LAS40 vs LGE and RMS40 vs LGE) were 
conducted to evaluate the null hypothesis that there is no correlation of the LGE technique in 
CMR and SAECG in the detection of myocardial fibrosis in the cohort (n = 35). In the fQRS 
analysis, the independent variable; LGE, included two groups: positive (108.2ms [90.2 – 
126.2], n = 17) and negative (115.7ms [97 – 134.5], n = 18); p=0.127. The assumption of 
normality was evaluated using histograms (see Figure 2) and found tenable for both groups. 
The assumption of longevity of variances was tested and found tenable using Levene’s Test 
F(1, 33) = 0.559, p =0.460. The ANOVA was not significant F(1 , 33) = 1.47, p = 0.23, 2 = 
0.02. In the LAS40 analysis, LGE groups were: positive (30.9ms [13.9 – 48], n = 17) and 
negative (36ms [22.8 – 49], n = 18). The assumption of normality was evaluated using 
histograms (see Figure 2) and found tenable for both groups. The assumption of longevity of 
variances was tested and also found tenable using Levene’s Test F(1, 33) = 1.126, p =0.296. 
The ANOVA for LAS40 was also not significant F(1 , 33) =0.95, p = 0.34, 2 = 0.02. In the 
RMS40 analysis, LGE groups were: positive (34.9 µV [7.4 – 62.5], n = 17) and negative 
(33.3µV [11 – 55.7], n = 18). The assumption of normality was evaluated using histograms 
(see Figure 2) and found tenable for both groups. The assumption of longevity of variances 
was tested and also found tenable using Levene’s Test F(1, 33) = 0.639, p =0.430. The 
ANOVA for RMS40 was not significant F(1 , 33) = 0.36, p= 0.85, 2 = 0.02. Figure 3 shows 







 Figure 2: Tests of Homogeneity of Variances 
 
Overall, the LVEF and LVEDV index measurements were normally distributed with means of 
60% ± 10.8% and 89mL/m2 ± 17.5mL/m2 respectively (Table 6). There was a notable 
difference of the mean LVEF in patients without LGE compared to those with LGE (64.5 ± 8.7  
vs 55.7 ± 11%, p = 0.014) and of the mean LVEDV index (82.5m ± 14.7 vs. 95.3 ± 18.1 mL/m2, 
 Levene 
Statistic 
df1 df2 Sig. 
fQRS Based on Mean .559 1 33 .460 
 Based on Median .242 1 33 .626 
 Based on Median 
and adjusted df 
.242 1 32.652 .626 
 Based on trimmed 
mean 
.496 1 33 .486 
LAS40 Based on Mean 1.126 1 33 .296 
 Based on Median 1.199 1 33 .281 
 Based on Median 
and adjusted df 
1.199 1 32.598 .282 
 Based on trimmed 
mean 
1.283 1 33 .266 
RMS40 Based on Mean .639 1 33 .430 
 Based on Median .267 1 33 .609 
 Based on Median 
and adjusted df 
.267 1 28.711 .609 
 Based on trimmed 
mean 
.489 1 33 .489 
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p = 0.028). The overall median RVEF and RVEDV index measurements were 53.5% (IQR 
41.6 - 60.3) and 96.4mL/m2 (84.9 – 122.6), respectively. An observed difference in the median 
RVEF of patients with and without LGE [47.7 (IQR 30.4 – 56.1) vs. 56.2% (IQR 48.1 – 63.3), 
p = 0.025) was noted and the median RVEDV index [116.2 (IQR 89.2 – 154.6) vs. 87.8 (IQR 
78.8 – 101.2) mL/m2, p = 0.003] is statistically significant. The LV mass index measurements 
followed a normal distribution with a mean of 64.2  ± 14.5 g/m2 and a significant difference in 
the LV mass index noted between those with and without LGE (72.5 ± 13.3 vs. 55.4 ± 10.2 
g/m2, p < 0.001).  LV maximal and minimal wall thickness had a mean of 10.3 ± 2mm and 6.89 
± 1.3 mm, retrospectively with no differences between the group with and without LGE. CMR 
LV regional wall motion abnormalities were detected in 4 patients of which 3 had LGE and 1 
with no LGE. CMR RV regional wall motion abnormalities were observed in 9 patients of which 
7 had LGE and the remaining 2 without LGE. (Figure 4) 
 




Figure 4: CMR image of a 15-year old male with ARVC 
 
Image courtesy of IMHOTEP Study 
Short axis image showing diffuse late gadolinium enhancement of the right ventricular free 
wall and patchy enhancement of the right ventricular septum . Patching enhancement of the 













Table 6. CMR findings 
 
 All 
n = 35 
LGE – 
n = 17 
LGE+ 




        Mean ±SD 
        Median (IQR) 
LVEDD/BSA (mL/m2) 
        Mean ±SD 
        Median (IQR) 
RVEF (%)*  
        Mean ±SD 
        Median (IQR) 
RVEDD/BSA (mL/m2) * 
        Mean ±SD 
        Median (IQR) 
LV mass/BSA (g/m2) 
        Mean ±SD 
        Median (IQR) 
LV maximal wall thickness (mm) 
        Mean ±SD 
        Median (IQR) 
LV minimal wall thickness (mm) 
        Mean ±SD 
        Median (IQR) 
LV RWMA, n (%) 










53.5 (41.6 - 60.3) 
 
107.2±33.3 
96.4(84.9 - 122.6) 
 
64.2 ±14.5 
62.1(53.3 – 75.7) 
 
10.3 ± 2 
10 (9 – 11) 
 
6.89 ±1.3 


















54.2(47.7 - 60.8) 
 
9.7±1.6 
10(8.5 – 10) 
 
6.9±1 







57.3(50.1 – 59.2) 
 
95.32±18.1 
97(83.93 – 108.5) 
 
44±16.4 






73.4(62.5 – 78) 
 
10.8±2.2 
11(9 – 13) 
 
6.8±1.6 



























*Non-parametric data – confirmed using visualization of the histogram and Shapiro-Wilk test 
for normality < 0.05 
 
LVEF – Left Ventricular Ejection Fraction 
LVEDD – Left Ventricular End-Diastolic Diameter 
BSA – Body Surface Area 
RVEF – Right Ventricular Ejection Fraction 
RVEDD – Right Ventricular End-Diastolic Diameter 







DISCUSSION AND CONCLUSION 
Discussion 
LGE CMR and SAECG are complementary investigations providing similar information in the 
detection and evaluation of fibrofatty change in ARVC and other cardiomyopathies. Whilst 
SAECG is a relatively cheap and ubiquitous investigation modality, CMR is a scarce resource 
in the South African context. Comparing the SAECG parameters (fQRS, LAS40, RMS40) with 
LGE in patients with definitive ARVC and other cardiomyopathies such as HCM and DCM we 
found no correlation. Our study therefore does not support a modification or revision of the 
current Task Force Criteria6 to include LGE as one of the diagnostic criteria as a means of 
further increasing the diagnostic sensitivity of CMR.  
 
We found patients presented at a younger age and were more likely to be male in keeping 
with known epidemiology as ARVC patients accounted for nearly fifty percent of the entire 
cohort. We found all patients were symptomatic at presentation; palpitations being the most 
prevalent symptom (77%), followed by pre-syncope (42.9%), chest pain (40%), syncope 
(37.1%) and dyspnoea (9%) with no significant statistical difference between those with and 
without LGE on CMR (p = 0.289). We found 28% had VT at presentation but unfortunately the 
morphology of the VT had not been characterised, 5.7% presented having survived cardiac 
arrest, 46% had documented VT on enrolment or follow-up and 43% had an ICD inserted 
subsequent to their initial presentation. Although VT and SCD were more frequently reported 
in LGE positive patients compared to LGE negative patients, the differences between the 
groups were not statistically significant (VT, 50% versus 41.2%, p 0.521; SCD, 11.1% versus 
0%, p = 0.157); a significant finding was expected as the frequency of VT is dependent on the 
severity of the disease3. 
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In comparing the SAECG to LGE CMR, we found the unfiltered QRS tended to be longer in 
patients with LGE compared to those without LGE (95.9 ±9.9 vs 88.1 ±10.3), this finding 
however was not statistically significant. Late potentials were more prevalent in patients with 
LGE on CMR compared to those without (61.1% vs 35.3% p = 0.127). Kamath et al examined 
the diagnostic and clinical value of the SAECG in a population of 87 genotyped ARVC 
probands diagnosed as affected or borderline by Task Force Criteria without the SAECG 
criterion against 103 controls and found that using 1 of 3 SAECG criteria contributed to 
increased sensitivity and specificity for the diagnosis of ARVC.20  Further analysis of the late 
potential parameters revealed RMS40 and fQRS duration had the greatest difference between 
the two groups (15% and 14.7%, respectively vs. 9.4% for HFLA < 40µV; p = 0.555). The 
median fQRS duration in those with LGE was prolonged, 114ms (IQR 102.3 – 119) compared 
to 111ms (IQR 99.5 -130) in those without. The median RMS40 was lower 23.5 µV (IQR 14.3 
– 47.5) in the group with LGE when compared to 33 µV (IQR 18.5 – 43.5) in the other. A one-
way analysis of variance conducted for each of the SAECG parameters found the correlation 
to LGE not statistically significant. 
 
Various studies have compared SAECG against other Task Force modalities in the diagnosis 
of ARVC with varying results. A study by Park et al correlating 2D echocardiography and 
SAECG in 33 ARVC patients found that the RVOT was the most frequently involved segment 
in ARVC and there was no significant correlation between parameters of the SAECG and 2D 
echocardiography for the entire patient population.21 Another study correlating SAECG with 
left and right endo-myocardial biopsy in 38 patients with VT and no clinical evidence of 
structural heart disease concluded the presence of late QRS potentials on the SAECG is 
useful in identifying patients with VT without clinically apparent heart disease who, despite 
normal function, have a moderate increase in myocardial fibrosis on biopsy.22  
 
We found the CMR measurements of LVEF and LVEDV index means to be within normal 
range when compared to the findings of Hudsmith et al who obtained LV and RV 
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measurements in 108 healthy volunteers23. The vast majority of patients in the cohort had 
definite ARVC and thus it was expected that there would be a significant difference of LVEF 
and LVEDV index means as the LV is affected in 75% cases of ARVC especially in phenotypes 
with early and predominant LV involvement24. The RVEF and RVEDV index means were 
expected and found to be lower than those of healthy volunteers as RV dilatation and 
dysfunction are the hallmarks of ARVC diagnosis but this result was confounded by the small 
population size as evident in the wide confidence interval.  The lower values did not, however, 
meet the 2010 ARVC Revised TFC for diagnosis of ARVC. The difference in the medians of 
the RVEDV index of patients with and without LGE was significant suggesting correlation 
between a high RVEDV index and LGE. The LGE patterns of the RV were not assessed further 
to delineate different patterns of ARVC. Although our study showed no correlation between 
SAECG and LGE in predicting myocardial scar tissue related ventricular arrhythmias and in 
the diagnosis of ARVC; a meta-analysis of 9 studies involving 1488 patients with non-ischemic 
cardiomyopathy followed on average for 30 months noted LGE presence in 38% of patients 
and was associated with an odds ratio of 3.3 for mortality and 5.3 for sudden cardiac death 
(SCD) or aborted SCD.25 Tandri et al evaluated the role of LGE CMR for non-invasive 
detection of fibrosis in ARVC and found CMR to have an excellent correlation with 
histopathology and predicted inducible VT on programmed electrical stimulation.14 
Our study has several limitations. The study included a small sample of patients and thus 
caution must be exercised in extrapolating the findings to a larger cohort of patients. It is also 
imperative to mention the base for IMHOTEP ARVC Registry is a tertiary institution, Groote 
Schuur Hospital where patients with a clinical suspicion of cardiomyopathy are referred to by 




Whilst SAECG is a known and reliable non-invasive study method in detecting myocardial 
fibrosis we have not shown its correlation to the presence of CMR LGE alone. This finding 
suggests fragmented electrical activity might appear with no significant relation to fibrofatty 
changes, necrosis and/or inflammation in the myocardium. However, further larger studies 
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